High EpCAM expression is linked to proliferation and lauren classification in gastric cancer

BMC Research Notes

Volumn 6, Issue 1, 2013, Pages

  Kroepil, Feride ^a   Dulian, Agnieszka ^a   Vallböhmer, Daniel ^a   Geddert, Helene ^c   Krieg, Andreas ^a   Vay, Christian ^a   Topp, Stefan A ^a   Schulte Am Esch, Jan ^a   Baldus, Stephan E ^a   Gires, Olivier ^b   Knoefel, Wolfram T ^a   Stoecklein, Nikolas H ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c St Vincent's Hospital   (Germany)

Author keywords

EpCAM expression; Gastric cancer; Ki 67; Laur n classification; Overall survival

Indexed keywords

ZIZIPHUS MAURITIANA;

CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; KI 67 ANTIGEN; TUMOR ANTIGEN;

ARTICLE; CELL PROLIFERATION; HUMAN; LYMPH NODE METASTASIS; METABOLISM; PATHOLOGY; PROGNOSIS; STOMACH MUCOSA; STOMACH TUMOR;

ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CELL PROLIFERATION; GASTRIC MUCOSA; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; PROGNOSIS; STOMACH NEOPLASMS;

EID: 84879805580     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-6-253     Document Type: Article

References (28)

1. Global cancer statistics, 2002. Parkin DM, Bray F, Ferlay J, Pisani P, CA Cancer J Clin 2005 55 74 108 (Pubitemid 40372904)
2. Validation of the seventh edition of the american joint committee on cancer TNM staging system for gastric cancer. Jung H, Lee HH, Song KY, Jeon HM, Park CH, Cancer 2011 117 11 2371 2378
3. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, et al. N Engl J Med 2006 355 11 20
4. The biology of the 17-1A antigen (Ep-CAM). Balzar M, Winter MJ, de Boer CJ, Litvinov SV, J Mol Med (Berl) 1999 77 699 712
5. The structural analysis of adhesions mediated by Ep-CAM. Balzar M, Prins FA, Bakker HA, Fleuren GJ, Warnaar SO, Litvinov SV, Exp Cell Res 1999 246 108 121 (Pubitemid 29393751)
6. Nuclear signalling by tumour-associated antigen EpCAM. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, Kieu C, Papior P, Baeuerle PA, Munz M, Gires O, Nat Cell Biol 2009 11 162 171
7. The tumour-associated antigen EpCAM upregulates the fatty acid binding protein E-FABP. Munz M, Zeidler R, Gires O, Cancer Lett 2005 225 151 157 (Pubitemid 40732778)
8. EpCAM regulates cell cycle progression via control of cyclin D1 expression. Chaves-Perez A, Mack B, Maetzel D, Kremling H, Eggert C, Harreus U, Gires O, Oncogene 2013 32 641 650
9. EpCAM in carcinogenesis: the good, the bad or the ugly. van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM, Rots MG, Carcinogenesis 2010 31 1913 1921
10. EpCAM: a potential antimetastatic target for gastric cancer. Du W, Ji H, Cao S, Wang L, Bai F, Liu J, Fan D, Dig Dis Sci 2010 55 2165 2171
11. EpCAM (CD326) finding its role in cancer. Baeuerle PA, Gires O, Br J Cancer 2007 96 417 423 (Pubitemid 46215211)
12. Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Seligson DB, Pantuck AJ, Liu X, Huang Y, Horvath S, Bui MH, Han KR, Correa AJ, Eeva M, Tze S, et al. Clin Cancer Res 2004 10 2659 2669 (Pubitemid 38509139)
13. EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis. Ralhan R, Cao J, Lim T, Macmillan C, Freeman JL, Walfish PG, BMC Cancer 2010 10 331
14. Prognostic significance of EpCAM-positive disseminated tumor cells in rectal cancer patients with stage I disease. Dhayat S, Sorescu S, Vallbohmer D, Kraus S, Baldus SE, Rehders A, Kropil F, Krieg A, Knoefel WT, Stoecklein NH, Am J Surg Pathol 2012 36 1809 1816
15. Expression of epithelial cell adhesion molecule (EpCam) in renal epithelial tumors. Went P, Dirnhofer S, Salvisberg T, Amin MB, Lim SD, Diener PA, Moch H, Am J Surg Pathol 2005 29 83 88 (Pubitemid 40023954)
16. The biology of the 17-1A antigen (Ep-CAM). Balzar M, Winter MJ, de Boer CJ, Litvinov SV, J Mol Med 1999 77 699 712
17. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Kononen J, Simon R, Sauter G, Baeuerle PA, Br J Cancer 2006 94 128 135 (Pubitemid 43088552)
18. Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. Songun I, Litvinov SV, van de Velde CJ, Pals ST, Hermans J, van Krieken JH, Br J Cancer 2005 92 1767 1772 (Pubitemid 40756490)
19. EpCAM is overexpressed in gastric cancer and its downregulation suppresses proliferation of gastric cancer. Wenqi D, Li W, Shanshan C, Bei C, Yafei Z, Feihu B, Jie L, Daiming F, J Cancer Res Clin Oncol 2009 135 1277 1285
20. Loss of membranous Ep-CAM in budding colorectal carcinoma cells. Gosens MJ, van Kempen LC, van de Velde CJ, van Krieken JH, Nagtegaal ID, Mod Pathol 2007 20 221 232 (Pubitemid 46422177)
21. Expression of Ep-CAM in intestinal metaplasia, gastric epithelial dysplasia and gastric adenocarcinoma. Joo M, Kim H, Kim MK, Yu HJ, Kim JP, J Gastroenterol Hepatol 2005 20 1039 1045 (Pubitemid 40961226)
22. The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O, Oncogene 2004 23 5748 5758 (Pubitemid 39093020)
23. Malignant progression in Barrett's esophagus: pathology and molecular biology. Mueller J, Werner M, Siewert JR, Recent Results Canc Res 2000 155 29 41
24. Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. Strohlein MA, Siegel R, Jager M, Lindhofer H, Jauch KW, Heiss MM, J Exp Clin Cancer Res 2009 28 18
25. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP, Nat Med 1998 4 844 847 (Pubitemid 28331029)
26. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, Ochiai A, Ruschoff J, Henkel T, Histopathology 2008 52 797 805 (Pubitemid 351724903)
27. Increased EpCAM expression in malignant insulinoma: potential clinical implications. Raffel A, Eisenberger CF, Cupisti K, Schott M, Baldus SE, Hoffmann I, Aydin F, Knoefel WT, Stoecklein NH, Eur J Endocrinol 2010 162 391 398
28. Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker. Stoecklein NH, Siegmund A, Scheunemann P, Luebke AM, Erbersdobler A, Verde PE, Eisenberger CF, Peiper M, Rehders A, Esch JS, et al. BMC Cancer 2006 6 165